Compare StocksMRNA vs UNH

Moderna, Inc. (MRNA) vs UnitedHealth Group Incorporated (UNH): Which Is the Better Buy in 2026?

As of 2026-06-19, MRNA is overvalued at $64, with a DCF intrinsic value of $6 and a margin of safety of -963%. UNH is fairly valued at $401, with an intrinsic value of $376 and a margin of safety of -7%. Of the two, UNH has the wider margin of safety.

MRNA
Moderna, Inc.
$63.96
VS
UNH
UnitedHealth Group Incorporated
$400.96

Rewards

MRNA
    UNH
    • UnitedHealth Group Incorporated scores 73/100 on the Economic Moat Score (Wide Moat), with revenue predictability as the strongest competitive dimension.

    Risks

    MRNA
    • ROIC has declined by 67.4 percentage points over the past 4 years, which may signal competitive erosion.
    • Gross margin of -69.9% is low, suggesting a competitive or commodity-like market with limited pricing power.
    • Moderna, Inc. scores only 17/100 on the Economic Moat Score, suggesting limited durable competitive advantages.
    UNH
    • ROIC has declined by 6.9 percentage points over the past 4 years, which may signal competitive erosion.
    • Gross margin of 18.8% is low, suggesting a competitive or commodity-like market with limited pricing power.
    • Free cash flow has declined at a 11.8% CAGR over the past 4 years — a concerning trend.

    Key Valuation Metrics

    Learn more →
    MRNA
    UNH
    Valuation
    $-20.00M
    Free Cash Flow
    $17.69B
    -0.08%
    FCF Yield
    4.86%
    N/A
    Trailing P/E
    30.17
    -15.21
    Forward P/E
    19.18
    Quality & Moat
    -26.47%
    ROIC
    15.60%
    -36.56%
    ROE
    12.18%
    -69.89%
    Gross Margin
    18.80%
    N/A
    PEG Ratio
    1.41
    Balance Sheet Safety
    Net cash
    Net Debt / Equity
    0.44
    N/A
    Interest Coverage
    N/A
    N/A
    Net Debt / EBITDA
    2.18
    0.00%
    Dividend Yield
    2.21%
    MRNA: 2Ties: 1UNH: 6
    MRNAUNH

    Historical Fundamentals

    Learn more →
    MRNA

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    UNH

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    $1 Retained Earnings Test

    Learn more →
    MRNA
    N/A
    Net losses over 3 years — test not applicable
    Company had negative cumulative retained earnings
    Σ Retained
    $-11.10B
    Δ Market Cap
    $-57.53B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
    UNH
    $-7.37
    created per $1 retained over 3 years
    Market Cap Declined
    Σ Retained
    $26.63B
    Δ Market Cap
    $-196.16B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Discounted Cash Flow (DCF) Analysis

    Learn more →
    MRNA
    962.8% Overvalued
    Price is 962.8% above estimated fair value
    Current Price: $63.96
    Fair Value: $6.02
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued
    UNH
    6.6% Overvalued
    Price is 6.6% above estimated fair value
    Current Price: $400.96
    Fair Value: $376.14
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued

    Reverse DCF — Market-Implied Growth

    Learn more →
    MRNA

    Requires positive FCF to compute implied growth rate.

    UNH

    What growth rate is the market pricing in at $401?

    +14.1%
    Market-Implied Owner Earnings Growth
    Standard FCF implies +9.8%

    The market implies +14.1% Owner Earnings growth, above historical trends.

    Standard FCF implies a demanding +9.8%, reflecting heavy growth investment.

    Economic Moat Score

    Learn more →
    MRNA
    17/100
    No Moat
    70+ Wide · 40-69 Narrow · <40 None

    No durable competitive advantage detected. The business shows limited evidence of pricing power, consistent returns, or capital efficiency.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.
    UNH
    73/100
    Wide Moat
    70+ Wide · 40-69 Narrow · <40 None

    Wide moat driven primarily by revenue predictability. Margin Stability is the area most vulnerable to competitive pressure.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.

    Forensic Accounting

    Learn more →
    MRNA

    Insufficient data for Beneish M-Score calculation (requires 2+ years).

    UNH
    -2.45
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Ownership Breakdown

    Learn more →
    MRNA
    Insiders 7.3%Institutions 78.9%Retail & Other 13.7%
    No. of Institutional Holders1,044
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
    UNH
    Insiders 0.2%Institutions 85.9%Retail & Other 13.8%
    No. of Institutional Holders4,020
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

    High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

    Insider Buying Activity

    Learn more →
    MRNA
    0
    Buys (3M)
    0
    Buys (12M)
    SAGAN PAUL L
    Director
    $1.00M
    @ $31.76 · 2025-03-03
    BANCEL STEPHANE J
    Chief Executive Officer
    $5.00M
    @ $31.22 · 2025-03-03
    Open market purchases · includes direct & indirect ownership · excludes option exercises
    UNH
    0
    Buys (3M)
    0
    Buys (12M)
    HEMSLEY STEPHEN J
    Chief Executive Officer
    $25.02M
    @ $288.57 · 2025-05-16
    REX JOHN F
    President
    $5.00M
    @ $291.12 · 2025-05-16
    GIL KRISTEN
    Director
    $1.00M
    @ $271.17 · 2025-05-15
    FLYNN TIMOTHY PATRICK
    Director
    $491,786
    @ $320.80 · 2025-05-14
    NOSEWORTHY JOHN H
    Director
    $93,647
    @ $312.16 · 2025-05-14
    FLYNN TIMOTHY PATRICK
    Director
    $511,575
    @ $511.57 · 2025-01-17
    Open market purchases · includes direct & indirect ownership · excludes option exercises

    Open market purchases · includes direct & indirect ownership · excludes option exercises.

    Insider Selling Activity

    Learn more →
    MRNA
    3
    Sells (3M)
    6
    Sells (12M)
    Total value (12M): $11.57M
    KLINGER SHANNON THYME
    Officer
    $173,550
    @ $50.00 · 2026-06-04
    HOGE STEPHEN
    President
    $2.58M
    @ $48.40 · 2026-05-15
    HUSSAIN SHAH ABBAS
    Director
    $264,952
    @ $46.63 · 2026-05-01
    KLINGER SHANNON THYME
    Officer
    $726,047
    @ $52.29 · 2026-03-02
    HOGE STEPHEN
    President
    $7.81M
    @ $48.84 · 2026-02-23
    HUSSAIN SHAH ABBAS
    Director
    $13,910
    @ $27.60 · 2025-12-09
    HUSSAIN SHAH ABBAS
    Director
    $8,736
    @ $28.00 · 2025-06-11
    KLINGER SHANNON THYME
    Officer
    $23,637
    @ $44.68 · 2024-12-09
    KLINGER SHANNON THYME
    Officer
    $4,849
    @ $43.29 · 2024-12-03
    HOGE STEPHEN
    President
    $13,595
    @ $43.30 · 2024-12-03
    KLINGER SHANNON THYME
    Officer
    $60,675
    @ $42.79 · 2024-11-29
    HOGE STEPHEN
    President
    $12,452
    @ $42.79 · 2024-11-29
    MOCK JAMES M
    Chief Financial Officer
    $60,761
    @ $42.79 · 2024-11-29
    HOGE STEPHEN
    President
    $12,771
    @ $46.10 · 2024-11-11
    MOCK JAMES M
    Chief Financial Officer
    $42,986
    @ $60.12 · 2024-10-07
    KLINGER SHANNON THYME
    Officer
    $40,539
    @ $73.57 · 2024-09-09
    KLINGER SHANNON THYME
    Officer
    $8,777
    @ $76.99 · 2024-09-03
    HOGE STEPHEN
    President
    $24,483
    @ $76.99 · 2024-09-03
    KLINGER SHANNON THYME
    Officer
    $12,640
    @ $78.02 · 2024-08-29
    HOGE STEPHEN
    President
    $23,408
    @ $78.03 · 2024-08-29
    MOCK JAMES M
    Chief Financial Officer
    $12,640
    @ $78.02 · 2024-08-29
    KLINGER SHANNON THYME
    Officer
    $104,722
    @ $79.39 · 2024-08-28
    MOCK JAMES M
    Chief Financial Officer
    $104,881
    @ $79.40 · 2024-08-28
    HOGE STEPHEN
    President
    $21,363
    @ $84.11 · 2024-08-12
    AFEYAN NOUBAR BOGHOS
    Director
    $1.80M
    @ $119.96 · 2024-07-31
    AFEYAN NOUBAR BOGHOS
    Director
    $1.77M
    @ $117.80 · 2024-07-24
    AFEYAN NOUBAR BOGHOS
    Director
    $1.84M
    @ $122.84 · 2024-07-17
    HOGE STEPHEN
    President
    $1.82M
    @ $121.12 · 2024-07-15
    AFEYAN NOUBAR BOGHOS
    Director
    $1.76M
    @ $117.08 · 2024-07-10
    MOCK JAMES M
    Chief Financial Officer
    $81,465
    @ $118.24 · 2024-07-08
    AFEYAN NOUBAR BOGHOS
    Director
    $1.91M
    @ $127.22 · 2024-06-26
    AFEYAN NOUBAR BOGHOS
    Director
    $2.00M
    @ $133.57 · 2024-06-18
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
    UNH
    1
    Sells (3M)
    1
    Sells (12M)
    Total value (12M): $284,000
    CONWAY PATRICK HUGH M.D.
    Officer
    $284,000
    @ $355.00 · 2026-04-23
    CONWAY PATRICK HUGH M.D.
    Chief Executive Officer
    $179,645
    @ $305.00 · 2025-06-10
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

    🎭 Mr. Market's Mood

    Learn more →
    MRNA
    FearGreed
    😏Greed(61/100)

    "Market is optimistic — be cautious and ensure you have a margin of safety"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
    UNH
    FearGreed
    😏Greed(68/100)

    "Market is optimistic — be cautious and ensure you have a margin of safety"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    ⚖️ Buffett Signal

    Learn more →
    MRNA
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Greed (61)
    UNH
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Greed (68)
    View MRNA Full AnalysisView UNH Full Analysis

    Frequently Asked Questions: MRNA vs UNH

    Is Moderna, Inc. or UnitedHealth Group Incorporated more undervalued in 2026?

    Based on our discounted cash flow model, UNH trades at a -6.6% margin of safety (intrinsic value $376 vs. price $401), compared to MRNA's -962.8% margin of safety (intrinsic $6 vs. $64).

    Which stock has a wider economic moat, Moderna, Inc. or UnitedHealth Group Incorporated?

    UNH scores 73/100 (Wide moat), while MRNA scores 17/100 (None moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

    Is Moderna, Inc. in financial distress?

    MRNA's Altman Z-Score of 2.5 places it in the Grey zone, signaling elevated bankruptcy risk. UNH scores 2.9 (Grey zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

    Which company has better free cash flow, Moderna, Inc. or UnitedHealth Group Incorporated?

    UnitedHealth Group Incorporated (UNH) generates a 4.9% free cash flow yield, compared to Moderna, Inc.'s -0.1%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

    Which stock has higher return on invested capital, Moderna, Inc. or UnitedHealth Group Incorporated?

    UNH earns 15.6% ROIC versus MRNA's -26.5%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.